Sugi Predict

Sugi Predict / Targets / SMCHD1

SMCHD1

Structural maintenance of chromosomes flexible hinge domain-containing protein 1 · A6NHR9 · SMCHD1 on Sugi Atlas →

1,894 patent compounds predicted against SMCHD1, 1,677 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to SMCHD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Low-Dose Danazol for the Treatment of Telomere Related Diseases PHASE2COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets PHASE1COMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Microcephaly Genetic Deficiency in Neural Progenitors nanCOMPLETED
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique nanUNKNOWN
Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis nanUNKNOWN
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies nanUNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome nanACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Impact of Ionizing Treatment on the Nuclear Structure of Human Spermatozoa. nanUNKNOWN
Telomere and Telomerase nanWITHDRAWN
The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopmental Disorders nanRECRUITING
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Tobacco and Sperm Genome: Effects of Smoking Cessation nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
PGT-A Versus Blastocyst Morphology Selection nanCOMPLETED
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMCHD1 binder may also engage these)

ProteinNameSimilarity
Q6P5D8 — 1.000 Q6P5D8 →
DNAJC13 DnaJ homolog subfamily C member 13 0.989 landscape →
Q8VDY4 — 0.988 Q8VDY4 →
Q69ZX6 — 0.988 Q69ZX6 →
P0CI65 — 0.986 P0CI65 →
B1AY13 — 0.986 B1AY13 →
Q8NG08 — 0.986 Q8NG08 →
P60670 — 0.985 P60670 →
Q61419 — 0.985 Q61419 →
USP24 Ubiquitin carboxyl-terminal hydrolase 24 0.985 landscape →
Q2I6J1 — 0.985 Q2I6J1 →
P34089 — 0.985 P34089 →
Q5R5T0 — 0.985 Q5R5T0 →
Q8WSR4 — 0.985 Q8WSR4 →
Q8CEC0 — 0.985 Q8CEC0 →
A0JM23 — 0.985 A0JM23 →
Q8C5W4 — 0.984 Q8C5W4 →
Q9ULT8 — 0.984 Q9ULT8 →
Q3B7T1 — 0.984 Q3B7T1 →
Q7SH49 — 0.984 Q7SH49 →
Q8CF97 — 0.984 Q8CF97 →
Q6AZT7 — 0.984 Q6AZT7 →
Q6PJI9 — 0.984 Q6PJI9 →
F4JSE7 — 0.984 F4JSE7 →
O95876 — 0.983 O95876 →
ITPR3 Inositol 1,4,5-trisphosphate-gated calcium channel ITPR3 0.983 landscape →
Q80VJ4 — 0.983 Q80VJ4 →
Q8R5F7 — 0.983 Q8R5F7 →
Q9Y6X9 — 0.983 Q9Y6X9 →
Q8C0M0 — 0.983 Q8C0M0 →